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The article by Swan et al. (2005) in this issue of Environmental Health
Perspectives reignites the issue of the role that phthalate exposure dur-
ing pregnancy may play in the etiology of reproductive disorders in
human males. It does so by providing the first evidence of an associa-
tion between phthalate exposure of mothers during pregnancy and
attenuation of androgen action in their male babies. If this association
is indicative of cause and effect, it will join together three key areas of
research, namely, testicular dysgenesis syndrome (TDS) disorders in
human males, induction of TDS-like disorders by phthalate adminis-
tration to laboratory animals during pregnancy (experimental studies),
and the widespread exposure of humans to various phthalates. 
TDS refers to a collection of disorders of newborn or young adult
males thought to have a common origin in fetal life as a result of tes-
ticular dysgenesis (Skakkebaek et al. 2001). These disorders include
cryptorchidism (testis maldescent) and hypospadias, the two most
common congenital malformations in newborns (2–4% and
0.3–0.7% incidence, respectively), testicular germ cell cancer, and low
sperm counts. Low sperm count affects approximately 20% of young
men in many European countries (Jorgensen et al. 2002), whereas
testicular cancer is the most frequent cancer of young men, and its
incidence has been increasing progressively in Caucasian men for the
past 50 years or more (Richiardi et al. 2004). An integral feature of
the TDS hypothesis is hormonal dysfunction of the fetal testis, in par-
ticular, reduced production of testosterone (Sharpe and Skakkebaek
2003). Because testosterone is largely responsible for transforming the
fetus into a male, TDS can be viewed as a sexual differentiation (i.e.,
masculinization) disorder. But where do phthalates come in?
Studies by several groups have shown that exposing pregnant
rats to certain phthalates (di-n-butyl, diethylhexyl phthalate or butyl
benzyl phthalate) during the period of sexual differentiation of the
pups results in a collection of disorders in the male offspring similar
to TDS disorders in men (Fisher et al. 2003; Mylchreest et al.
1998). More tellingly, the phthalate exposure results in focal testicu-
lar dysgenesis (Barlow et al. 2004; Fisher et al. 2003; Mahood et al.
2005) and associated suppression of hormone production (testos-
terone, insulin-like factor 3) by the fetal testis (Parks et al. 2000;
Thompson et al. 2004; Wilson et al. 2004). One indication that the
phthalate-exposed pups are “undermasculinized” is that they exhibit
a reduction in anogenital distance (AGD) (Ema and Miyawaki 2001;
Gray et al. 2000; Mylchreest et al. 2000; Zhang et al. 2004). AGD
in male rats is normally about twice that in females, and a similar sex
difference is evident in humans (Salazar-Martinez et al. 2004). This
difference is a direct reflection of growth-stimulating actions of
androgens, such as testosterone, on the perineum in fetal life; it is
therefore an indicator of the level of androgen action in the fetus
and thus of the masculinization process. Reduced AGD = reduced
androgen levels or action.
Reduction in AGD in rats occurs after dosing the pregnant
mothers with phthalates at concentrations > 250 mg/kg/day (Ema
and Miyawaki 2001; Mylchreest et al. 2000; Zhang et al. 2004).
Humans are exposed to a range of phthalates (Koch et al. 2003; Silva
et al. 2004), with urinary concentrations of the primary metabolites
of key phthalates in the range of 3–40 µg/L (150–1,000 µg/L for
monoethyl phthalate). Although the phthalate dose administered to
rats and the concentration of urinary phthalate metabolites in
humans is difficult to compare directly, the consensus view has been
that humans are not exposed to phthalates at
levels capable of affecting fetal testis hormone
production and masculinization in rats. Swan
et al. (2005) challenge this view by showing a
negative relationship between the anogenital index (AGI) in boys
2–30 months of age and the level of phthalate metabolites in maternal
urine during the index pregnancy. At face value, this suggests that
phthalates have similar adverse effects on fetal testosterone production
in humans as they do in rats. However, this effect must occur at
lower levels of phthalate exposure in humans, because reduced AGI
was found in boys born to mothers with phthalate levels similar to
those found in about 25% of the U.S. population (Silva et al. 2004).
If this interpretation is correct, it provides a strong likelihood that
phthalate exposure in humans is one potential cause of TDS dis-
orders, a conclusion that has widespread public health implications.
So how certain can we be about this interpretation?
Swan et al. (2005) show an association between maternal phthalate
exposure and AGI in boys—they do not show that one caused the
other or that the phthalates caused reduced testosterone production.
They also do not show that phthalate exposure caused abnormalities
(all boys were “normal”), although the collateral finding that boys with
a lower AGI had a higher incidence of cryptorchidism and reduced
penis size, when compared with boys with a higher AGI, is consistent
with an abnormal reduction in testosterone levels. Measurement of
urinary, salivary, or blood (e.g., cord blood) testosterone levels in rela-
tion to AGI in future studies should help to clarify this issue, as should
establishment of more detailed normative data for AGI in boys and
girls and the evaluation of AGI in boys with established evidence of
deficient androgen action, such as those with hypospadias.
The findings of Swan et al. (2005) need to be confirmed inde-
pendently. This is not a criticism of the quality of the study (which
is excellent) but a standard requirement of good science. Better
understanding of the comparative fetal exposure of humans to
phthalates and those in the experimental studies in rats, for exam-
ple, by comparison of phthalate metabolite levels in amniotic fluid,
would also be instructive. What is also urgently needed is improved
knowledge about how humans, in particular pregnant women, are
exposed to phthalates (Silva et al. 2004). What are the most impor-
tant routes: air, water, diet, or personal care products? One sensible,
precautionary response to the present findings is for women who are
planning a pregnancy to minimize their exposure to phthalates, but
they cannot be guided how to do so unless we know their primary
routes of exposure.
Two final notes of caution for readers who consider it wise to
assume that phthalates cause TDS in humans. First, the association
of AGI with phthalate exposure could be fortuitous; for example,
the same lifestyle practices that expose a woman to phthalates might
themselves cause the reduction in testosterone/AGI or expose her to
other factors that cause this effect. Second, the TDS hypothesis
argues that any factor that causes testicular dysgenesis (mal-
development) is likely to result in TDS disorders, and this includes
well-established genetic disorders (Skakkebaek et al. 2001); it is also
likely to be affected by maternal lifestyle. Therefore, phthalates will
not be the only cause of TDS. For the moment, we do not even
know they are a cause, but it is undoubtedly a possibility that
deserves urgent further study.
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